Mydecine Innovations Group Inc. Share Price NEO Exchange
Equities
MYCO
CA62849F2008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 CAD | +45.83% | +29.63% | -61.11% |
02-23 | Mydecine Innovations Closes Partial Debt Settlement | MT |
02-02 | Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director | CI |
Sales 2021 | 0.01 0.01 0.6 | Sales 2022 | - | Capitalization | 7.58M 10.34M 603M |
---|---|---|---|---|---|
Net income 2021 | -28M -38.21M -2.23B | Net income 2022 | -11M -15.01M -875M | EV / Sales 2021 | 5,249,560,605 x |
Net Debt 2021 | 3.01M 4.1M 239M | Net Debt 2022 | 153K 209K 12.2M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.13
x | P/E ratio 2022 |
-0.44
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.04% |
1 day | +45.83% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Roscow
FOU | Founder | - | 26/09/13 |
Damon Michaels
FOU | Founder | - | 26/09/13 |
David Bartch
CEO | Chief Executive Officer | - | 21/06/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Bartch
CEO | Chief Executive Officer | - | 21/06/18 |
Damon Michaels
FOU | Founder | - | 26/09/13 |
Robert Roscow
FOU | Founder | - | 26/09/13 |
1st Jan change | Capi. | |
---|---|---|
+2.59% | 42.75B | |
+47.70% | 41.61B | |
+12.21% | 41.34B | |
-8.83% | 26.59B | |
+7.92% | 25.49B | |
-22.51% | 18.12B | |
+31.23% | 12.24B | |
-1.47% | 11.76B | |
+8.57% | 11B |
- Stock Market
- Equities
- MYCOF Stock
- MYCO Stock